GAMBACORTI PASSERINI CARLO

Posizione organizzativa:

Ruolo:

Professore ordinario

Settore scientifico disciplinare:

MALATTIE DEL SANGUE (MED/15)

Afferenza:

E-mail:

Telefono:

0264488362
0264488057

Stanza:

U08, Piano: P04, Stanza: 4041
Via Cadore, 48 - 20900 MONZA

U8, Piano: IV, Stanza: 4-12
Via Cadore, 48 - 20900 MONZA

Crespiatico, I., Bossi, E., Brioschi, F., Piazza, R., Mologni, L., & Gambacorti‐Passerini, C. (2020). An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. CLINICAL CASE REPORTS, 8(1), 71-74. Dettaglio
Gambacorti-Passerini, C., Coutre, P., & Piazza, R. (2020). The role of bosutinib in the treatment of chronic myeloid leukemia. FUTURE ONCOLOGY, 16(2), 4395-4408. Dettaglio
Ramazzotti, D., Angaroni, F., Maspero, D., Gambacorti-Passerini, C., Antoniotti, M., Graudenzi, A., et al. (2020). Characterization of intra-host SARS-CoV-2 variants improves phylogenomic reconstruction and may reveal functionally convergent mutations [Rapporto tecnico]. Dettaglio
Bossi, E., Brioschi, F., Steidl, C., Baretta, S., Cantu, S., Verga, L., et al. (2019). Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy. Intervento presentato a: Congress of the Italian-Society-of-Hematology, Rome, Italy. Dettaglio
Hehlmann, R., Cortes, J., Zyczynski, T., Gambacorti-Passerini, C., Goldberg, S., Mauro, M., et al. (2019). Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. AMERICAN JOURNAL OF HEMATOLOGY, 94(1), 46-54. Dettaglio

Futuri studenti